Fiscal 2009 Financial Results. May 10, 2010

Transcription

1 Fiscal 2009 Financial May 10, 2010

2 Forward-Looking Statements This presentation contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to productrelated forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations nor provide medical advice of any kinds. 1

3 Overview of 2

4 Financial (Consolidated & Non-Consolidated) <Consolidated> Achievement FY2008 Sales Operating income Ordinary income Net income <Non-consolidated> Achievement FY2008 Sales Operating income Ordinary income Net income

5 of The 2 nd Mid-Term Business Plan (Consolidated) (billion yen) Sales % (billion yen) R&D expenses * %** 0 FY2005 FY2006 FY2007 FY2008 (billion yen) 100 Operating income 0 (billion yen) 100 FY2005 FY2006 FY2007 FY2008 Net income **: is 20.1% compared with FY2008 excluding IPRD expenses, 9.6 billion yen % FY2005 FY2006 FY2007 FY2008 * % FY2005 FY2006 FY2007 FY *: FY2008 includes former Sciele Pharma acquisition cost *

6 Financial Position and Cash Flows (Consolidated) <Financial position> 3/31/2010 3/31/2009 Total assets Net assets Equity ratio Net assets per share (yen) 1, <Cash flows> FY2008 Net cash provided by operating activities Net cash provided by investing activities Net cash provided by financing activities (0.8) (149.0) (4.9) (110.1) Net increase (decrease) 46.1 (16.0) 62.1 Cash and cash equivalents at end of period

7 Sales by Segments (Consolidated) Achievement FY2008 Prescription drugs (0.5) (0.7) Crestor Flomox (12.1) (3.3) Rinderon (1.3) (0.1) Claritin (6.4) (0.6) Flumarin (13.9) (1.4) OxyContin Vancomycin (24.5) (2.0) Imunace (24.8) (1.5) Irbetan Finibax Differin Pirespa Avelox (32.1) (0.5) Rapiacta Export/Overseas operating Shionogi Pharma, Inc Doripenem Contract manufacturing OTC and quasi-drugs Diagnostics (11.2) (0.4) Royalty income Crestor Others (8.2) (0.3) Total

8 Statements of Income (Consolidated) Achievement FY2008 Sales [Royalty] [52.0] [57.0] [109.6] [36.8] [54.6] [20.2] Cost of sales 26.4 [32.5] [34.4] [37.2] Gross profit SG&A expenses Selling & general expenses R&D expenses (1.9) (1.0) Operating income Non-operating income and expenses L 2.0 L L 0 - L 1.9 Ordinary income Extraordinary income and loss - P L Income before income taxes Total income taxes Net income

9 FY2010 Financial 8

10 FY2010 Financial (Consolidated & Non-Consolidated) <Consolidated> FY2010 Sales Operating income Ordinary income Net income <Non-consolidated> FY2010 Sales Operating income Ordinary income Net income (6.8) (2.7) Due to change in the accounting periods, forecasts in FY2010 include 15 months for the U.S. subsidiaries. 9

11 FY2010 Sales by Segments (Consolidated) FY2010 Prescription drugs Crestor Irbetan Cymbalta Total of 3 key products OxyContin Finibax Differin Pirespa Rapiacta Total of 5 new products Flomox (20.8) (5.0) Rinderon (6.0) (0.6) Claritin (10.3) (0.9) Flumarin (24.1) (2.1) Vancomycin (36.5) (2.2) Imunace (19.4) (0.9) Export/Overseas operating Shionogi Pharma, Inc Doripenem Contract manufacturing (66.3) (4.9) OTC and quasi-drugs Diagnostics (4.9) (0.1) Royalty income Crestor Others (26.2) (1.1) Total Due to change in the accounting periods, forecasts in FY2010 include 15 months for the U.S. subsidiaries. 10

12 Shareholder Return Dividend Policy Steadily raise the consolidated payout ratio forecasts: 36 yen per share as planned FY2010 forecasts: 40 yen per share (yen) Dividend Payout ratio (consolidated) 29.3% 29.6% 59.9% % % 40 60% 40% % % 0 FY2005 FY2006 FY2007 FY2008 FY2010 0% 11